Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
BE HEARD: Share your story with staff of the FDA about your experience or your loved one’s living with #CarcinoidSyndrome (CS). #FDA’s Patient Affairs and NORD are hosting
NET patient, oncologist, and NETRF Board Member Mark Lewis, MD, is a native Scotsman who moved to Austin, TX as a young man when his
The Cancer Moonshot’s success relies on ‘collaborative oncology.’ Just last month, the Neuroendocrine Tumor Research Foundation (NETRF) hosted our first in-person/hybrid research symposium since going
We introduced you to Lilly Pearce back in 2019, when she was about halfway through her senior year of high school and six months post-operation
Additional US study sites are now participating in an ongoing clinical trial of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide as a first or second
After being virtual since 2020, the North American Neuroendocrine Tumor Society (NANETS) met in person for its annual meeting in Washington DC in late October. NETRF CEO Elyse Gellerman and Director of Patient Education Jessica Thomas attended the NANETS Symposium to talk with NET specialists, a number of NETRF research grantees, and other NET patient advocacy groups. They joined more than 400 attendees dedicated to better understanding neuroendocrine cancer, improving patient care, and supporting patients through advocacy and education.
Brittany Holzhauer had her whole future planned. A self-professed “dreamer” with incredible determination, she started her career as pharmacist in 2018 and with her husband Luke, welcomed her first child, Lorelei, in June of 2019.
“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.” Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here.
A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.
A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).